मूलभूत आँकड़े
| CIK | 1723069 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tiziana Life Sciences Ltd
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 5, 2025 |
Tiziana Life Sciences Announces Purchase of Shares by Chairman Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Shares by Chairman BOSTON, MA, September 5, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chair |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execu |
|
| August 14, 2025 |
Exhibit 99.1 Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy BOSTON, MA, August 14, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ant |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 11, 2025 |
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy Exhibit 99.1 FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy NEW YORK, August 11, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| July 21, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer’s Patient NEW YORK, July 21, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today |
|
| June 13, 2025 |
Exhibit 99.1 Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center NEW YORK, June 13, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal for |
|
| June 13, 2025 |
Tiziana Life Sciences to Present at the Bio International Convention Exhibit 99.1 Tiziana Life Sciences to Present at the Bio International Convention NEW YORK, June 13, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its CEO, Ivor Elrif |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| May 23, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease NEW YORK, May 23, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoc |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 15, 2025 |
Exhibit 99.1 Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer’s Disease NEW YORK, May 15, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 12, 2025 |
Tiziana Life Sciences Announces Purchase of Shares by Chairman Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Shares by Chairman New York, May 12, 2025 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and F |
|
| May 9, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab NEW YORK, May 9, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 8, 2025 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F/A for the fiscal year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United S |
|
| May 8, 2025 |
Exhibit 12.1 CERTIFICATION I, Ivor Elrifi, certify that: 1. I have reviewed this annual report on Form 20-F/A of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| May 8, 2025 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F/A of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| May 8, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F/A for the fiscal year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United S |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 6, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| May 6, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| May 6, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis ● Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. ● All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores. ● TSPO-PET imaging showed |
|
| May 6, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd: We consent to the incorporation by reference of our report dated May 6, 2025 with respect to the consolidated balance sheet as of December 31, 2024 and 2023 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for eac |
|
| May 6, 2025 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec |
|
| May 6, 2025 |
TIZIANA LIFE SCIENCES LTD INSIDER TRADING POLICY Exhibit 19.1 TIZIANA LIFE SCIENCES LTD INSIDER TRADING POLICY 1. PURPOSE This Insider Trading Policy (this “Policy”) states the policy with respect to transactions in the securities of Tiziana Life Sciences Ltd. (the “Company”), and the handling of confidential information about the Company and other companies with which the Company does business. The Company’s Board of Directors has adopted this |
|
| May 6, 2025 |
Exhibit 12.1 CERTIFICATION I, Gabriele Cerrone, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38723 NOTIFICATION OF LATE FILING ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 23, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial NEW YORK, April 23, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti |
|
| April 2, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial NEW YORK, April 2, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 27, 2025 |
Tiziana Life Sciences Ltd. Clarendon House, 2 Church Street, Hamilton HM 11, Tiziana Life Sciences Ltd. Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda March 27, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Tiziana Life Sciences Ltd. Form F-3 Registration Statement Filed March 24, 2025 File No. 333-286064 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and R |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 25, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial NEW YORK, March 25, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclo |
|
| March 24, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025. As filed with the Securities and Exchange Commission on March 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tiziana Life Sciences Ltd. (Exact Name of registrant as Specified in its charter) Not Applicable (Translation of registrant’s name into English) Bermuda Not Applicable ( |
|
| March 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) TIZIANA LIFE SCIENCES LTD. |
|
| March 17, 2025 |
Tiziana Life Sciences to Present at the 37th Annual Roth Conference Exhibit 99.1 Tiziana Life Sciences to Present at the 37th Annual Roth Conference NEW YORK, March 17, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 14, 2025 |
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule Exhibit 99.1 Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule NEW YORK, March 14, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it |
|
| March 4, 2025 |
Exhibit 99.1 Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial NEW YORK, March 4, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, toda |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| February 27, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti- CD3 Therapy in Traumatic Brain Injury ● Traumatic brain injury is a leading cause of death and disability ● Currently, there is no treatment to prevent the long-term effects of traumatic brain injury ● Findings could translate into treating intracerebral |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| February 25, 2025 |
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter Exhibit 99.1 Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter NEW YORK, February 25, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nas |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| February 21, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC NEW YORK, February 21, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| February 18, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program NEW YORK, February 18, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibod |
|
| February 11, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease NEW YORK, February 11, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, t |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 24, 2025 |
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 Exhibit 99.1 Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 NEW YORK, January 23, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 22, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab NEW YORK, January 22, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 |
|
| January 10, 2025 |
Exhibit 99.1 Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 NEW YORK, January 10, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 8, 2025 |
Exhibit 99.1 Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab’s Potential in the Treatment of Neurological Disease NEW YORK, January 8, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully h |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| December 17, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab NEW YORK, December 17, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ant |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 4, 2024 |
Exhibit 99.1 Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers NEW YORK, December 4, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralu |
|
| November 19, 2024 |
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association Exhibit 99.1 Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association NEW YORK, November 19, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today annou |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| November 1, 2024 |
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million Exhibit 99.1 Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough i |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| November 1, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT October 30, 2024 Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners” or the “Place |
|
| November 1, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this” Agreement”) is dated as of October 30, 2024, between Tiziana Life Sciences Ltd., an exempted company incorporated under the laws of Bermuda (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, “Purchaser”). WHEREAS, subject to the terms and conditions s |
|
| November 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-252441 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 3, 2022) 5,263,158 Common Shares We are offering 5,263,158 common shares pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each common share to the purchaser identified in the securities purchase agreement dated October 30, 2024, by and among us |
|
| November 1, 2024 |
Exhibit 99.1 Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data NEW YORK, November 1, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a full |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-38723 Tiziana Life Sciences Ltd. (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| October 30, 2024 |
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study Exhibit 99.1 Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study NEW YORK, October 30, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today a |
|
| October 25, 2024 |
Up to $50,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-252441 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 3, 2022) Up to $50,000,000 Common Shares We have entered into an Open Market Sale Agreement℠, dated October 25, 2024, which we refer to as the Sales Agreement, with Jefferies LLC, or Jefferies, relating to the issuance and sale of our common shares offered by this prospectus supplement. In |
|
| October 25, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 25, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tiziana Life Sciences Ltd., an exempted company incorporated under the laws of Bermuda (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “ |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-38723 Tiziana Life Sciences Ltd. (Exact Name of Registrant as Specified in Its Charter) 4th Floor, 14-14 Conduit Street London W1S 2XJ (Address of registrant’s principal |
|
| October 18, 2024 |
Exhibit 99.1 Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) Update and Interim Results for the Six Months Ended 30 June 2024 NEW YORK, October 18, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced interim financial results for the six m |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execu |
|
| September 19, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease NEW YORK, September 19, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant |
|
| August 19, 2024 |
Tiziana Life Sciences Appoints New Chief Executive Officer Exhibit 99.1 Tiziana Life Sciences Appoints New Chief Executive Officer NEW YORK, August 19, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi a |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 14, 2024 |
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule Exhibit 99.1 Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule NEW YORK, August 14, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| July 24, 2024 |
Tiziana Life Sciences Granted FDA Fast Track Designation Exhibit 99.1 Tiziana Life Sciences Granted FDA Fast Track Designation NEW YORK, July 24, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administratio |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 28, 2024 |
Tiziana Receives $3.4 Million in Non-Dilutive Funding Exhibit 99.1 Tiziana Receives $3.4 Million in Non-Dilutive Funding NEW YORK, June 28, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate up |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 26, 2024 |
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab Exhibit 99.1 Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab NEW YORK, June 26, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranas |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 11, 2024 |
Exhibit 99.1 FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis NEW YORK, June 11, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received acceptance of its submission for intranasa |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 6, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab ● Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months. ● FDA Allowance for an additional 20 P |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 4, 2024 |
Exhibit 99.1 Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab NEW YORK, June 4, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibo |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| May 30, 2024 |
Exhibit 99.1 Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research NEW YORK, May 30, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana’s Sci |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 13, 2024 |
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab Exhibit 99.1 Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab NEW YORK, May 13, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal f |
|
| May 10, 2024 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| May 10, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd: We consent to the incorporation by reference of our report dated May 10, 2024 with respect to the consolidated balance sheet as of December 31, 2023 and 2022 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for ea |
|
| May 10, 2024 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| May 10, 2024 |
Exhibit 2.1 Description of Securities General Our share capital comprises common shares of par value $0.001 each and preference shares of par value $0.001 each. Subject to a resolution of shareholders to the contrary and any special rights previously conferred on the holders of any existing shares or class of shares, the Board is authorized to issue any unissued shares on such terms and conditions |
|
| May 10, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd: We hereby consent to the incorporation by reference in Registration Statement on Form F-3 (File No. 333-252441) of our report dated May 20, 2022 with respect to the consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the year en |
|
| May 10, 2024 |
Exhibit 12.1 CERTIFICATION I, Gabriele Cerrone, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| May 10, 2024 |
Tiziana Life Sciences Ltd. CLAWBACK POLICY Exhibit 97 Tiziana Life Sciences Ltd. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this C |
|
| May 10, 2024 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38723 NOTIFICATION OF LATE FILING ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 25, 2024 |
Exhibit 99.1 Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab NEW YORK, April 25, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative |
|
| April 23, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program NEW YORK, April 23, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announce |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 22, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program ● 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up ● All Patients Have Either Stabilized or Improved on Foralumab Treatment and No Patients Declined in Key Clinical |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 19, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platform session at the Annual Meeting |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 18, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology - Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans - NEW YORK, April 18, 2024 – Tiziana Life Sciences, Lt |
|
| April 11, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology NEW YORK, April 11, 2024 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentati |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 5, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease ● Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) ● Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studies ● Neuroinflammation modulation may be synerg |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 8, 2024 |
Exhibit 99.1 Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients NEW YORK, January 08, 2024 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six ou |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| January 5, 2024 |
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 Exhibit 99.1 Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 NEW YORK, January 5, 2024 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will prese |
|
| January 5, 2024 |
Exhibit 99.1 Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity- Associated Inflammation NEW YORK, January 5, 2024 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing |
|
| December 29, 2023 |
Exhibit 99.1 Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced interim financial results for the six mon |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 19, 2023 |
Exhibit 99.1 Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis NEW YORK, December 19, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal for |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 4, 2023 |
Exhibit 99.1 Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar NEW YORK, December 4, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Me |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| December 1, 2023 |
Exhibit 99.1 Tiziana Life Sciences Ltd Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK TO BE HELD AS A “REMOTE MEETING” ONLY YOU ARE NOTIFIED that the 2023 annual general meeting (“AGM”) of Tiziana Life Sciences Ltd (the “Company”) will be held via video and telephonic conference (in accordance with the Company’s by-law 26.1) on Thursday 14t |
|
| November 30, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis NEW YORK, November 30, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully e |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execut |
|
| November 1, 2023 |
Exhibit 99.1 Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 NEW YORK, November 1, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| October 18, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment ● Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing Initiative ● Greater Than 1 year Safety Exposure to anti-CD3 Foralumab Has Been Well-Tolerated ● At-Home Dosing Li |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| October 16, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab ● Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL™ Fatigue scores. ● Data was presented at ECTRIM |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| October 13, 2023 |
Exhibit 99.1 Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) ● Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed) ● Foralumab to advance into Phase 2 |
|
| October 11, 2023 |
Exhibit 99.1 Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress · Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disab |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execu |
|
| September 26, 2023 |
Exhibit 99.1 Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis NEW YORK, September 26, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held a |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execu |
|
| September 8, 2023 |
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Exhibit 99.1 Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-on |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal execu |
|
| September 6, 2023 |
Exhibit 99.1 Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance ● The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” ● FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal an |
|
| September 1, 2023 |
Exhibit 1.1 TIZIANA LIFE SCIENCES LTD. Common Shares ($0.001 par value per share) At Market Issuance Sales Agreement September 1, 2023 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Tiziana Life Sciences Ltd., an exempted company incorporated under the laws of Bermuda (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities |
|
| September 1, 2023 |
Up to US$50,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-252441 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 3, 2022) Up to US$50,000,000 Common Shares We have entered into an At Market Issuance Sales Agreement, dated September 1, 2023, which we refer to as the Sales Agreement, with B. Riley Securities, Inc. (“Agent” or “B. Riley”), relating to the issuance and sale of our common shares offered b |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 0001723069 Tiziana Life Sciences Ltd. (Exact Name of Registrant as Specified in Its Charter) 4th Floor, 14-14 Conduit Street London W1S 2XJ (Address of registrant’s princi |
|
| August 23, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology NEW YORK, August 23 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presenta |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 23, 2023 |
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer Exhibit 99.1 Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer ● Leadership Addition Strengthens Company’s Commitment to Advancing Innovative Therapies NEW YORK, August 23, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug de |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 17, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer’s Disease NEW YORK, August 17, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug deliver |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executiv |
|
| August 15, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease ● Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody ● Trial to be overseen by Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System NEW YORK, August 15, 20 |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| July 21, 2023 |
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice Exhibit 99.1 Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on July 19, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that th |
|
| June 13, 2023 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F/A for the fiscal year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United S |
|
| June 13, 2023 |
Exhibit 12.1 CERTIFICATION I, Gabriele Cerrone, certify that: 1. I have reviewed this annual report on Form 20-F/A of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| June 13, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd: We consent to the incorporation by reference in the Registration Statement on Form F-3 ( File No. 333-252441) of our report dated April 26, 2023 with respect to the consolidated balance sheet for the year ended December 31, 2022 and the related consolidated statement of operat |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| June 13, 2023 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F/A of Tiziana Life Sciences plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| June 13, 2023 |
Consent of Independent Registered Public Accounting Firm EX-15.1 6 f20f2022a1ex15-1tizianalife.htm CONSENT OF MAZARS LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 ( File No. 333-252441) of our report dated May 20, 2022 with respect to the consolidated balance sheet for the year ende |
|
| June 13, 2023 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences plc’s Annual Report on Form 20-F/A for the fiscal year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United S |
|
| June 13, 2023 |
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer Exhibit 99.1 Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer NEW YORK, June 13, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Off |
|
| June 5, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis ● Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvements ● Phase 2a trial in na-SPMS on track to |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 25, 2023 |
Exhibit 99.1 Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET NEW YORK, May 25, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, to |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| May 23, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform NEW YORK, May 23, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull Corporate Co |
|
| May 17, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17 NEW YORK, May 17, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer, is presenting a |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive o |
|
| April 27, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference ● There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate ● Intranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severity ● Intranasal fo |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 26, 2023 |
Exhibit 12.1 CERTIFICATION I, Gabriele Cerrone, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| April 26, 2023 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of Tiziana Life Sciences ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec |
|
| April 26, 2023 |
Annual Lease for 14-15 Conduit Street, London W1S 2XJ United Kingdom Exhibit 4.5 Dated 2022 (1) CLERVILLE INVESTMENT MANAGEMENT LLP - and - (2) TIZIANA LIFE SCIENCES Limited LEASE OF PART Fourth Floor (rear), 14/15 Conduit Street, London W1S 2XJ Mishcon de Reya LLP Africa House 70 Kingsway London WC2B 6AH Tel: 020 3321 7000 Fax: 020 3006 8956 Ref: 60174.7 E-mail: [email protected] TABLE OF CONTENTS No. Heading Page 1. definitions and interpretation 1 1.1 P |
|
| April 26, 2023 |
Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of Tiziana Life Sciences Ltd: We consent to the incorporation by reference of our report dated April 26, 2023 with respect to the consolidated balance sheet for the year ended December 31, 2022 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity |
|
| April 26, 2023 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences ltd’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| April 26, 2023 |
Exhibit 4.7 LEASE AGREEMENT THIS LEASE AGREEMENT (the “Lease”), made this 29th day of August, 2022, by and between Tiziana Life Sciences Ltd (hereinafter referred to as Lessee) and Tabor Farms, LLC a Pennsylvania Limited Liability Corporation (hereinafter referred to as Lessor). WITNESSETH Lessor, for and in consideration of the prompt payment of the rent as specified in this Lease as well as the |
|
| April 26, 2023 |
Exhibit 99.1 Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update NEW YORK, April 26, 2023 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ende |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| April 26, 2023 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Tiziana Life Sciences ltd’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United Sta |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 24, 2023 |
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule Exhibit 99.1 Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule NEW YORK, April 24, 2023 - Tiziana Life Sciences Ltd.. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the Nasdaq Stock Market LLC (“N |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 20, 2023 |
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023 Exhibit 99.1 Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023 · Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023 · Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filing · Alzheimer’s patients will be administered 3-months of intranasal foralumab to |
|
| April 18, 2023 |
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes Exhibit 99.1 Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes ● CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi ● Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 dia |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 13, 2023 |
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID Exhibit 99.1 Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillion The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab d |
|
| April 10, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai ● Exhibition will run from March 31st to May 21st, 2023, at Prada Rong Zhai ● Scientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 4, 2023 |
Exhibit 99.1 Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage ● Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke ● Data shows behavioral outcomes improvement at one month in model of intracerebral hemorrhage (hemorrhagic stroke) ● Modulation of neuroinflammation |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| April 4, 2023 |
6-K 1 ea176463-6ktiziana.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapsid |
|
| April 4, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference ● Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) ● Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to |
|
| March 31, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden ● Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) ● Modulat |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 28, 2023 |
Exhibit 99.1 Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS · First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease · Tiziana received FDA Type C Meeting Minutes for prop |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 22, 2023 |
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO New York, March 22, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive O |
|
| March 22, 2023 |
6-K 1 f6k032223tizianalife.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheaps |
|
| March 21, 2023 |
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO New York, March 21, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive O |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 20, 2023 |
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO New York, March 20, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive O |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 17, 2023 |
Exhibit 99.1 Tiziana Life Sciences Highlighted in Forbes Article Article entitled “New T Cell Antibody Treatment Improves Outcomes For Covid Patients” reviews the company’s first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases NEW YORK, March 17, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tizia |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 17, 2023 |
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO NEW YORK, March 17, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chie |
|
| March 17, 2023 |
6-K 1 ea175398-6ktiziana.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapsid |
|
| March 15, 2023 |
Exhibit 99.1 Grant of share options NEW YORK, March 15, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the grant of the following share options to directors and members of senior management: Matthew Davis Chief Medical Officer and acting Chie |
|
| March 15, 2023 |
6-K 1 ea175251-6ktizianalife.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Chea |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive |
|
| March 8, 2023 |
Tiziana Life Sciences Announces Publication in Exhibit 99.1 Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab ● Illustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing th |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant?s principal executi |
|
| January 5, 2023 |
News Service Announcement, dated January 5, 2023 EX-99.1 2 ea171310ex99-1tizianalife.htm NEWS SERVICE ANNOUNCEMENT, DATED JANUARY 5, 2023 Exhibit 99.1 |
|
| January 4, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer NEW YORK, January 4, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (?Tiziana? or the ?Company?), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the Investigational New D |
|
| January 4, 2023 |
6-K 1 ea171195-6ktizianalife.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Ch |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2023 Commission File Number: 001-38723 Tiziana Life Sciences LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant?s principal executi |
|
| January 3, 2023 |
Exhibit 99.1 Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab ? The second Expanded Access patient (EA2) demonstrated additional clinical improvement in the Expanded Disability Status Scale (EDSS), a FDA recognized standard clinical outcome a |
|
| December 30, 2022 |
Exhibit 99.1 Tiziana Life Sciences Ltd (?Tiziana? or ?the Company?) Updated Interim Results for the Six Months Ended 30 June 2022 London, 29 December 2022 ? Tiziana Life Sciences Ltd (?Tiziana?, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months end |
|
| December 30, 2022 |
EX-99.2 3 ea171021ex99-2tiziana.htm CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2022 Exhibit 99.2 Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) Updated Interim Results for the Six Months Ended 30 June 2022 London, 29 December 2022 – Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approach |
